NASDAQ:CARA

Cara Therapeutics Competitors

$28.41
-0.78 (-2.67 %)
(As of 04/12/2021 02:45 PM ET)
Add
Compare
Today's Range
$27.97
Now: $28.41
$29.49
50-Day Range
$18.08
MA: $20.11
$27.47
52-Week Range
$12.30
Now: $28.41
$29.65
Volume35,987 shs
Average Volume844,661 shs
Market Capitalization$1.42 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.7

Competitors

Cara Therapeutics (NASDAQ:CARA) Vs. SRPT, ALLK, BPMC, PRGO, SDGR, and GLPG

Should you be buying CARA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Cara Therapeutics, including Sarepta Therapeutics (SRPT), Allakos (ALLK), Blueprint Medicines (BPMC), Perrigo (PRGO), Schrödinger (SDGR), and Galapagos (GLPG).

Sarepta Therapeutics (NASDAQ:SRPT) and Cara Therapeutics (NASDAQ:CARA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends.

Institutional & Insider Ownership

89.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 67.0% of Cara Therapeutics shares are owned by institutional investors. 5.9% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 5.7% of Cara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Sarepta Therapeutics and Cara Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sarepta Therapeutics191202.50
Cara Therapeutics00403.00

Sarepta Therapeutics presently has a consensus price target of $150.4762, suggesting a potential upside of 114.45%. Cara Therapeutics has a consensus price target of $34.50, suggesting a potential upside of 19.67%. Given Sarepta Therapeutics' higher probable upside, equities analysts clearly believe Sarepta Therapeutics is more favorable than Cara Therapeutics.

Profitability

This table compares Sarepta Therapeutics and Cara Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sarepta Therapeutics-121.30%-61.62%-23.02%
Cara Therapeutics-360.35%-64.36%-53.22%

Risk & Volatility

Sarepta Therapeutics has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500. Comparatively, Cara Therapeutics has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500.

Valuation and Earnings

This table compares Sarepta Therapeutics and Cara Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sarepta Therapeutics$380.83 million14.57$-715,080,000.00($9.71)-7.20
Cara Therapeutics$19.89 million71.24$-106,370,000.00($2.49)-11.41

Cara Therapeutics has lower revenue, but higher earnings than Sarepta Therapeutics. Cara Therapeutics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Sarepta Therapeutics beats Cara Therapeutics on 10 of the 14 factors compared between the two stocks.

Cara Therapeutics (NASDAQ:CARA) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, earnings and profitability.

Earnings & Valuation

This table compares Cara Therapeutics and Allakos' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cara Therapeutics$19.89 million71.24$-106,370,000.00($2.49)-11.41
AllakosN/AN/A$-85,370,000.00($1.89)-55.60

Allakos has lower revenue, but higher earnings than Cara Therapeutics. Allakos is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cara Therapeutics and Allakos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cara Therapeutics-360.35%-64.36%-53.22%
AllakosN/A-29.18%-27.70%

Risk and Volatility

Cara Therapeutics has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500. Comparatively, Allakos has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Cara Therapeutics and Allakos, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cara Therapeutics00403.00
Allakos00403.00

Cara Therapeutics presently has a consensus price target of $34.50, indicating a potential upside of 19.67%. Allakos has a consensus price target of $181.50, indicating a potential upside of 72.68%. Given Allakos' higher probable upside, analysts plainly believe Allakos is more favorable than Cara Therapeutics.

Institutional & Insider Ownership

67.0% of Cara Therapeutics shares are owned by institutional investors. Comparatively, 65.4% of Allakos shares are owned by institutional investors. 5.7% of Cara Therapeutics shares are owned by insiders. Comparatively, 44.8% of Allakos shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Allakos beats Cara Therapeutics on 7 of the 11 factors compared between the two stocks.

Blueprint Medicines (NASDAQ:BPMC) and Cara Therapeutics (NASDAQ:CARA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, institutional ownership, profitability and earnings.

Insider & Institutional Ownership

67.0% of Cara Therapeutics shares are held by institutional investors. 3.8% of Blueprint Medicines shares are held by insiders. Comparatively, 5.7% of Cara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Blueprint Medicines and Cara Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Blueprint Medicines$66.51 million81.70$-347,690,000.00($7.27)-12.90
Cara Therapeutics$19.89 million71.24$-106,370,000.00($2.49)-11.41

Cara Therapeutics has lower revenue, but higher earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Blueprint Medicines and Cara Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Blueprint Medicines41.08%43.72%33.35%
Cara Therapeutics-360.35%-64.36%-53.22%

Analyst Ratings

This is a breakdown of current recommendations for Blueprint Medicines and Cara Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Blueprint Medicines06712.64
Cara Therapeutics00403.00

Blueprint Medicines presently has a consensus target price of $111.00, indicating a potential upside of 18.30%. Cara Therapeutics has a consensus target price of $34.50, indicating a potential upside of 19.67%. Given Cara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cara Therapeutics is more favorable than Blueprint Medicines.

Risk and Volatility

Blueprint Medicines has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Cara Therapeutics has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500.

Summary

Blueprint Medicines beats Cara Therapeutics on 8 of the 15 factors compared between the two stocks.

Perrigo (NYSE:PRGO) and Cara Therapeutics (NASDAQ:CARA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Valuation and Earnings

This table compares Perrigo and Cara Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Perrigo$4.84 billion1.12$146.10 million$4.0310.02
Cara Therapeutics$19.89 million71.24$-106,370,000.00($2.49)-11.41

Perrigo has higher revenue and earnings than Cara Therapeutics. Cara Therapeutics is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Perrigo and Cara Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Perrigo-0.13%9.78%4.92%
Cara Therapeutics-360.35%-64.36%-53.22%

Risk and Volatility

Perrigo has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Cara Therapeutics has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Perrigo and Cara Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Perrigo04102.20
Cara Therapeutics00403.00

Perrigo presently has a consensus price target of $52.00, suggesting a potential upside of 27.98%. Cara Therapeutics has a consensus price target of $34.50, suggesting a potential upside of 19.67%. Given Perrigo's higher possible upside, equities analysts clearly believe Perrigo is more favorable than Cara Therapeutics.

Insider and Institutional Ownership

82.7% of Perrigo shares are owned by institutional investors. Comparatively, 67.0% of Cara Therapeutics shares are owned by institutional investors. 0.3% of Perrigo shares are owned by company insiders. Comparatively, 5.7% of Cara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Perrigo beats Cara Therapeutics on 8 of the 14 factors compared between the two stocks.

Schrödinger (NASDAQ:SDGR) and Cara Therapeutics (NASDAQ:CARA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Schrödinger and Cara Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Schrödinger01302.75
Cara Therapeutics00403.00

Schrödinger presently has a consensus price target of $85.50, suggesting a potential upside of 15.14%. Cara Therapeutics has a consensus price target of $34.50, suggesting a potential upside of 19.67%. Given Cara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cara Therapeutics is more favorable than Schrödinger.

Profitability

This table compares Schrödinger and Cara Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Schrödinger-19.92%-7.25%-5.33%
Cara Therapeutics-360.35%-64.36%-53.22%

Valuation and Earnings

This table compares Schrödinger and Cara Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Schrödinger$85.54 million60.15$-24,570,000.00N/AN/A
Cara Therapeutics$19.89 million71.24$-106,370,000.00($2.49)-11.41

Schrödinger has higher revenue and earnings than Cara Therapeutics.

Institutional & Insider Ownership

41.3% of Schrödinger shares are held by institutional investors. Comparatively, 67.0% of Cara Therapeutics shares are held by institutional investors. 5.7% of Cara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Cara Therapeutics beats Schrödinger on 6 of the 11 factors compared between the two stocks.

Cara Therapeutics (NASDAQ:CARA) and Galapagos (NASDAQ:GLPG) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, profitability, analyst recommendations and dividends.

Profitability

This table compares Cara Therapeutics and Galapagos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cara Therapeutics-360.35%-64.36%-53.22%
Galapagos-70.67%-11.78%-5.58%

Analyst Ratings

This is a summary of recent ratings and target prices for Cara Therapeutics and Galapagos, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cara Therapeutics00403.00
Galapagos211402.12

Cara Therapeutics presently has a consensus price target of $34.50, indicating a potential upside of 19.67%. Galapagos has a consensus price target of $143.7273, indicating a potential upside of 85.50%. Given Galapagos' higher possible upside, analysts plainly believe Galapagos is more favorable than Cara Therapeutics.

Valuation & Earnings

This table compares Cara Therapeutics and Galapagos' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cara Therapeutics$19.89 million71.24$-106,370,000.00($2.49)-11.41
Galapagos$1.00 billion5.06$167.83 million$5.4614.19

Galapagos has higher revenue and earnings than Cara Therapeutics. Cara Therapeutics is trading at a lower price-to-earnings ratio than Galapagos, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

67.0% of Cara Therapeutics shares are owned by institutional investors. Comparatively, 11.2% of Galapagos shares are owned by institutional investors. 5.7% of Cara Therapeutics shares are owned by insiders. Comparatively, 2.9% of Galapagos shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Cara Therapeutics has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500. Comparatively, Galapagos has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Summary

Galapagos beats Cara Therapeutics on 8 of the 13 factors compared between the two stocks.


Cara Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$69.87-1.0%$5.60 billion$380.83 million-8.93
Allakos logo
ALLK
Allakos
1.7$105.08-0.1%$5.58 billionN/A-38.35
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$93.75-0.4%$5.46 billion$66.51 million17.30
Perrigo logo
PRGO
Perrigo
2.5$40.39-0.3%$5.41 billion$4.84 billion-673.05
Schrödinger logo
SDGR
Schrödinger
1.5$73.49-0.6%$5.17 billion$85.54 million0.00Insider Selling
Galapagos logo
GLPG
Galapagos
1.3$77.46-0.5%$5.10 billion$1.00 billion-11.74
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
1.8$55.89-1.1%$4.68 billionN/A0.00
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.77-2.5%$4.47 billion$6.87 million-7.22Analyst Report
Analyst Revision
News Coverage
Gap Up
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$70.93-2.2%$4.31 billionN/A-5.78Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.03-0.7%$4.26 billion$204.89 million-36.29Gap Up
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$76.39-1.3%$4.12 billion$1.11 billion24.56
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$64.86-2.2%$4.00 billion$806.43 million-9.19Unusual Options Activity
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$76.46-3.3%$3.87 billionN/A-21.78News Coverage
LEGN
Legend Biotech
1.2$27.87-2.1%$3.76 billion$64.39 million0.00Gap Up
I-Mab logo
IMAB
I-Mab
1.4$47.48-8.8%$3.72 billion$4.31 million-1.64Gap Up
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$52.72-0.1%$3.67 billion$117.91 million-10.69
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$48.11-2.7%$3.44 billion$36.13 million-71.81
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.74-0.6%$3.40 billion$114.62 million-7.56Analyst Revision
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.31-0.6%$3.35 billion$306.98 million-6.77
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.48-0.2%$3.34 billionN/A-5.59
Insmed logo
INSM
Insmed
1.2$31.12-1.9%$3.27 billion$136.47 million-11.97
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.34-0.2%$3.26 billion$339.08 million-11.83
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$87.55-1.0%$3.20 billion$26.52 million-7.71
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$114.83-1.8%$3.16 billionN/A-57.13Gap Up
Arvinas logo
ARVN
Arvinas
1.5$61.52-3.2%$3.10 billion$42.98 million-24.03
Alkermes logo
ALKS
Alkermes
1.4$18.93-0.5%$3.03 billion$1.17 billion-41.15Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$67.94-0.5%$2.99 billion$421.03 million23.92Analyst Report
Analyst Revision
MorphoSys logo
MOR
MorphoSys
0.3$22.12-1.1%$2.94 billion$80.43 million105.34
Organogenesis logo
ORGO
Organogenesis
1.0$22.66-0.8%$2.92 billion$260.98 million-377.67Gap Down
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.02-4.0%$2.80 billion$901.90 million-22.33
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.73-0.1%$2.79 billion$644.77 million-10.38
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.52-0.7%$2.66 billion$306.49 million25.30
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.76-0.2%$2.56 billion$60,000.00-9.86News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$59.47-7.2%$2.56 billionN/A0.00
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$146.90-4.5%$2.55 billion$120.28 million-148.38
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.03-1.8%$2.53 billion$2.11 million-8.66
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$44.02-0.5%$2.52 billion$25 million-8.80
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$41.67-5.4%$2.43 billionN/A-22.90
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.30-1.2%$2.43 billion$182.24 million-8.09
Cryoport logo
CYRX
Cryoport
1.9$51.10-2.3%$2.38 billion$33.94 million-88.10Insider Selling
Xencor logo
XNCR
Xencor
1.2$40.41-0.1%$2.35 billion$156.70 million-28.86
Amarin logo
AMRN
Amarin
1.6$5.81-2.1%$2.33 billion$429.76 million-116.18
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$30.90-1.3%$2.22 billion$15 million-16.18
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$44.02-0.6%$2.18 billion$963.01 million13.67
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$63.51-7.8%$2.10 billionN/A-27.03
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.96-0.6%$2.01 billion$410,000.00-6.08
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.15-0.2%$1.99 billion$23.90 million-16.24Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.00-1.9%$1.98 billionN/A-19.33
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$24.65-3.2%$1.95 billion$103.54 million-18.53Gap Up
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.